Type 2 diabetes affects more than 530 million adults worldwide and is now the leading cause of preventable blindness, end-stage renal failure, and non-traumatic limb amputation. Tight glycaemic control reduces microvascular complications by 25–40%; modern agents (SGLT-2 inhibitors, GLP-1 receptor agonists, dual PPAR agonists) also cut cardiovascular and renal events independently of HbA1c. MedsBase carries 51 oral and injectable diabetes medications across every major drug class, supplied by WHO-GMP certified manufacturers, with discreet worldwide shipping.
Biguanides — metformin (first-line). Metformin lowers HbA1c by ~1.0–1.5 points, is weight-neutral or weight-losing, has a low hypoglycaemia risk, and is on the WHO Essential Medicines List. We stock metformin sustained-release as Biciphage 1000 SR, Glycomet SR, Diabetrol SR, en Metford — all once-daily SR formulations chosen for better GI tolerability than IR tablets.
Sulfonylureas — second-line oral secretagogues. SUs work by closing pancreatic K-ATP channels and forcing insulin release; they cut HbA1c by 1.0–1.5 points but carry hypoglycaemia and weight-gain risk. We carry the second-generation glimepiride (Amaryl, Glimda, Glimith, Glypride, Healmaryl), gliclazide MR (Glide, Glizid) — the lowest-hypoglycaemia SU and preferred in older patients — the older glibenclamide/glyburide (Daonil, Glybovin), and glipizide (Glynase, Glynase XL).
SU + metformin fixed-dose combinations. Once metformin alone fails to maintain HbA1c <7%, an SU is the cheapest and most studied add-on. Single-tablet combinations improve adherence: glimepiride+metformin (Amaryl M, Glycomet-GP, Glibaheal M), gliclazide+metformin (Glinil M), glibenclamide+metformin (Glucored), glipizide+metformin (Glynase-MF), and pioglitazone+metformin+glimepiride triple (Glisen PM).
Thiazolidinediones (TZDs) — pioglitazone. Insulin sensitisers acting on PPAR-γ that are particularly useful in NAFLD/NASH and patients with severe insulin resistance. Carries weight-gain, fluid retention, and bone-fracture risk; not for use in heart failure. We stock pioglitazone monotherapy (Pioz 15, P-Glitz) and pioglitazone-based combinations (Cyblex MV, Glycoheal, Pioglit Mf Forte).
DPP-4 inhibitors (gliptins) — weight-neutral, low hypoglycaemia. Block degradation of incretin hormones GLP-1 and GIP, prolonging post-meal insulin release. HbA1c reduction is modest (~0.5–0.8 points) but tolerability is excellent. We carry sitagliptin (Januvia) and its metformin combination (Janumet), vildagliptin (Galvus), saxagliptin (Onglyza), linagliptin (Trajenta) and its combination (Trajenta Duo), and teneligliptin (Ziten).
SGLT-2 inhibitors — cardio- and reno-protective beyond glycaemia. Block renal glucose reabsorption, causing urinary glucose loss. Reduce major adverse cardiovascular events, heart-failure hospitalisations, and progression of chronic kidney disease independently of HbA1c effect; recommended add-on for any patient with established CV disease, heart failure, or CKD. Class risks include genital mycotic infections and (rare) euglycaemic ketoacidosis. We stock dapagliflozin (Forxiga), empagliflozin (Jardiance), canagliflozin (Invokana), and the empagliflozin+linagliptin fixed-dose Glyxambi.
Meglitinides — rapid post-prandial secretagogues. Like sulfonylureas they trigger insulin release, but with a faster onset and shorter duration — useful for patients with prominent post-meal glucose excursions or irregular meal patterns. NovoNorm (repaglinide) and Glinate (nateglinide) are taken with each meal.
Alpha-glucosidase inhibitors — post-prandial spike control. Acarbose (Glucobay), miglitol (Mignar), and voglibose (PPG, Voglibite) work locally in the small intestine to slow carbohydrate digestion. HbA1c reduction is modest (0.5–0.8 points) but post-meal glucose drops sharply. Particularly effective in carbohydrate-rich diets.
Specialty agents. Lipaglyn (saroglitazar 4 mg) is a unique dual PPAR-α/γ agonist for diabetic dyslipidaemia and NAFLD/NASH — cuts triglycerides 40–50%, raises HDL, and reduces liver fat. Biodib 30 is a vildagliptin+metformin combination capsule.
Rapid-acting insulin pens. Pre-filled disposable analogue insulin pens for mealtime cover. Apidra SoloStar contains insulin glulisine; NovoRapid FlexPen contains insulin aspart. Both have a 5–15 minute onset, peak in 1–3 hours, and last 3–5 hours — closely matching post-meal glucose curves.
Adjunctive nutritional support. Methycobal Injectie (methylcobalamin) is used to treat metformin-induced and diabetic peripheral neuropathy — long-term metformin depletes vitamin B12, and replenishment improves neuropathic symptoms.
Note on Minirin. Minirin tablets en Minirin Nasal Spray contain desmopressin and treat diabetes insipidus, primary nocturnal enuresis, and nocturia — not type 2 diabetes mellitus. Despite the shared name, the two diseases are unrelated.
All medications on this page are FDA-approved generics manufactured under WHO-GMP standards. Discreet worldwide shipping to 50+ countries. 4.9★ from 1,400+ customers.